Essilor Archives - Page 3 of 24

Essilor and Luxottica Launch “Ray-Ban Authentic” Enhanced with Essilor Technology in Canada

Monday, February 15 2021 | 14 h 36 min | News, Press Release

EssilorLuxottica is launching the first commercial product leveraging the strength of the new Group by strategically combining the expertise of...

Essilor and Luxottica Launch First Joint Product Offering in U.S.: “Ray-Ban Authentic”

Friday, January 15 2021 | 15 h 56 min | New Products, News, Press Release

EssilorLuxottica is launching the first commercial product leveraging the strength of the new Group by strategically combining the expertise...

ClickCheck: Bringing Vision Care to Underserved Communities

Saturday, January 9 2021 | 07 h 57 min | New Products, News, Press Release

One of the key barriers to bringing vision care to the developing world is the lack of affordable testing tools and Essilor’s ClickCheck™ is...

World Sight Day 2020: Essilor Teams Engaged Despite the Challenges!

Friday, November 20 2020 | 11 h 24 min | News, Press Release

COVID-19 may have somewhat hampered plans, but it certainly did not deter Essilorians from marking an important date in the year for the Group –...

Essilor and FIA Renew and Deepen Partnership to Lead Global Change on Vision and Safe Mobility

Thursday, November 12 2020 | 07 h 45 min | News, Press Release

Jean Todt, President of the Fédération Internationale de l’Automobile (FIA) and the United Nations Secretary General’s Special Envoy for Road...

« Previous 1 2 3 4 5 … 24 Next »

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Tag: Essilor

Essilor and Luxottica Launch “Ray-Ban Authentic” Enhanced with Essilor Technology in Canada

Essilor and Luxottica Launch First Joint Product Offering in U.S.: “Ray-Ban Authentic”

ClickCheck: Bringing Vision Care to Underserved Communities

World Sight Day 2020: Essilor Teams Engaged Despite the Challenges!

Essilor and FIA Renew and Deepen Partnership to Lead Global Change on Vision and Safe Mobility

Featured Posts

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement